Regeneron Pharmaceuticals Inc (REGN)
824.48
+7.83
(+0.96%)
USD |
NASDAQ |
Nov 07, 16:00
824.50
+0.02
(+0.00%)
After-Hours: 07:00
Regeneron Pharmaceuticals Revenue (TTM): 13.85B for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 13.85B |
| June 30, 2024 | 13.49B |
| March 31, 2024 | 13.10B |
| December 31, 2023 | 13.12B |
| September 30, 2023 | 13.10B |
| June 30, 2023 | 12.67B |
| March 31, 2023 | 12.37B |
| December 31, 2022 | 12.17B |
| September 30, 2022 | 13.71B |
| June 30, 2022 | 14.23B |
| March 31, 2022 | 16.51B |
| December 31, 2021 | 16.07B |
| September 30, 2021 | 13.54B |
| June 30, 2021 | 12.38B |
| March 31, 2021 | 9.198B |
| December 31, 2020 | 8.497B |
| September 30, 2020 | 7.938B |
| June 30, 2020 | 7.387B |
| March 31, 2020 | 7.013B |
| December 31, 2019 | 6.558B |
| September 30, 2019 | 5.057B |
| June 30, 2019 | 4.976B |
| March 31, 2019 | 5.007B |
| December 31, 2018 | 5.146B |
| September 30, 2018 | 6.365B |
| Date | Value |
|---|---|
| June 30, 2018 | 6.203B |
| March 31, 2018 | 6.065B |
| December 31, 2017 | 5.872B |
| September 30, 2017 | 5.517B |
| June 30, 2017 | 5.236B |
| March 31, 2017 | 4.979B |
| December 31, 2016 | 4.860B |
| September 30, 2016 | 4.732B |
| June 30, 2016 | 4.649B |
| March 31, 2016 | 4.435B |
| December 31, 2015 | 4.104B |
| September 30, 2015 | 3.808B |
| June 30, 2015 | 3.396B |
| March 31, 2015 | 3.063B |
| December 31, 2014 | 2.820B |
| September 30, 2014 | 2.628B |
| June 30, 2014 | 2.499B |
| March 31, 2014 | 2.291B |
| December 31, 2013 | 2.105B |
| September 30, 2013 | 1.909B |
| June 30, 2013 | 1.740B |
| March 31, 2013 | 1.586B |
| December 31, 2012 | 1.378B |
| September 30, 2012 | 1.087B |
| June 30, 2012 | 762.00M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
6.558B
Minimum
Dec 2019
16.51B
Maximum
Mar 2022
11.84B
Average
12.88B
Median
Revenue (TTM) Benchmarks
| Amgen Inc | 32.53B |
| Eli Lilly and Co | 40.86B |
| Pfizer Inc | 59.37B |
| Biogen Inc | 9.608B |
| Vertex Pharmaceuticals Inc | 10.63B |